Investment
Features
FeesSafety
Academy
More
Pluang+

CarGurus beats Q2 2026 expectations with 13% revenue growth, driven by AI tools and strong cash flow.

Company Fundamentals
08 Aug 2026
Seeking Alpha
View Source
Bullish
pluang ai news

CarGurus reported better-than-expected Q2 2026 results, showing 13% revenue growth and gains in dealer engagement thanks to AI-driven tools like PriceVantage and VINMax. The company is expanding internationally and maintains a clean balance sheet with aggressive share buybacks. Management expects 10–15% revenue growth and improved EBITDA margins for the full year, supporting a positive outlook despite the stock trading at a modest 4% gain year-to-date and an undervalued forward EV/EBITDA multiple of 10x.

More News

Law firm investigates Hyliion for alleged misleading info causing stock drop, offers investors potential compensation.

Law firm investigates Hyliion for alleged misleading info causing stock drop, offers investors potential compensation.

The Rosen Law Firm is investigating potential securities claims against Hyliion Holdings Corp. following allegations that the company misled investors with materially false business information. This comes after a short-seller report questioned the l...

Market News
Bearish
3 hours ago
ConocoPhillips upgraded to Buy after strong Q2 and positive oil outlook, with steady strategy ahead.

ConocoPhillips upgraded to Buy after strong Q2 and positive oil outlook, with steady strategy ahead.

ConocoPhillips was upgraded from Hold to Buy following robust Q2 results and a positive outlook on oil prices. The company's Lower-48 shale assets continue to perform well operationally and financially. The CEO transition to Andrew O'Brien is expecte...

Analyst Insights
Bullish
4 hours ago
Roivant Sciences shifts to commercial biopharma with $4.7B cash, eyeing FDA approval for brepocitinib by 2026

Roivant Sciences shifts to commercial biopharma with $4.7B cash, eyeing FDA approval for brepocitinib by 2026

Roivant Sciences is evolving from an asset-monetization platform into a commercial-stage biopharma company, supported by a strong cash position of $4.7 billion that reduces near-term dilution risk. The company is preparing to commercialize brepocitin...

Market News
Bullish
4 hours ago
KLA stock drops 10.7% on China export fears despite strong earnings and $325 price target.

KLA stock drops 10.7% on China export fears despite strong earnings and $325 price target.

KLA Corporation's stock fell 10.74% recently due to concerns over U.S. export restrictions to China, which accounts for about 30% of its revenue. Despite this, KLA reported strong earnings and forward guidance, with a consensus analyst target of $230...

Analyst Insights
Bullish
4 hours ago
Ethereum whales buy 80,000 ETH, pushing price near $1,923 with strong bullish momentum.

Ethereum whales buy 80,000 ETH, pushing price near $1,923 with strong bullish momentum.

Ethereum's price recovered to around $1,923, supported by large whale purchases totaling 80,000 ETH worth $152 million. The Whale Sentiment Index rose to near 66, indicating strong buying interest from major holders. Despite one long-term whale selli...

Technical Signals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App